Early experience with a hybrid accelerated radiotherapy schedule for locally advanced head and neck cancer

Head and Neck

Volumn 29, Issue 8, 2007, Pages 720-730

  Nuyts, Sandra ^a   Dirix, Piet ^a   Hermans, Robert ^a   Poorten, Vincent Vander ^a   Delaere, Pierre ^a   Weltens, Caroline ^a   Van Den Bogaert, Walter ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Altered fractionation; Head and neck cancer; Radiotherapy; Toxicity

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DERMATITIS; DYSPHAGIA; FEASIBILITY STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RADIATION DOSE; SCORING SYSTEM;

ADULT; AGED; ANALYSIS OF VARIANCE; BELGIUM; CARCINOMA, SQUAMOUS CELL; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34547957264     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20565     Document Type: Article

References (54)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Dobrossy L. Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev 2005; 24:9-17.
3. Lament EB, Vokes EE. Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncol 2001;2:261-269.
4. Vermorken JB. Medical treatment in head and neck cancer. Ann Oncol 2005;16:258-264.
5. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. Medical progress. N Engl J Med 2001;345:1890-1900.
6. Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S. Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res 1998;18:4779-4786.
7. Budach W, Hehr T, Budach V, Belka C, Dietz K. A metaanalysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006;6:28-42.
8. Ang KK, Garden AS. editors. Radiotherapy for head and neck cancers: indications and techniques, 2nd ed. Philadelphia, PA: Lippincott; 2002.
9. Fletcher GH. Regaud lecture: perspectives on the history of radiotherapy. Radiother Oncol 1988;12:253-271.
10. Thames HD, Bentzen SM, Turesson I, Overgaard M, Van den Bogaert W. Fractionation parameters for human tissues and tumors. Int J Radiat Biol 1989;56:701-710.
11. Thames HD, Bentzen SM, Turesson I, Overgaard M, Van den Bogaert W. Time-dose factors in radiotherapy: a review of the human data. Radiother Oncol 1990;19: 219-235.
12. Van den Bogaert W, van der Schueren E. Radiotherapy with thrice-a-day-fractionation in a short overall time. Int J Radiat Oncol Biol Phys 1981;7:1133-1134.
13. Garden AS. Altered fractionation for head and neck cancer. Oncology (Williston Park) 2001;15:1326-1332.
14. Nguyen LN, Ang KK. Radiotherapy for cancer of the head and neck: altered fractionation regimens. Lancet Oncol 2002;3:693-701.
15. Bourhis J, Etessami A, Wilbaut P, et al. Altered fractionated radiotherapy in the management of head and neck carcinomas: advantages and limitations. Curr Opin Oncol 2004;16:215-219.
16. Withers HR, Peters LJ, Thames HD, Fletcher GH. Hyperfractionation. Int J Radiat Oncol Biol Phys 1982;8:1807-1809.
17. Baumann M, Bentzen SM, Ang KK. Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data. Radiother Oncol 1998;46:127-130.
18. Van den Bogaert W, Van der Leest A, Rijnders A, Delaere P, Thames H, Van der Schueren E. Does tumor control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer? Radiother Oncol 1995;36:177-182.
19. Overgaard J, Alsner J, Eriksen J, Horsman MR, Grau C. Importance of overall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck. Rays 2000;25:313-319.
20. Horiot JC, van den Bogaert W, Ang KK, et al. European organization for research and treatment of cancer trials using radiotherapy with multiple fractions per day. A 1978-1987 survey. Front Radiat Ther Oncol 1988;22:149-161.
21. Pinto L, Canary P, Araujo C, Bacelar SC, Souhami L. Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages II and TV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1991;21:557-562.
22. Horiot JC, Le Fur R, N'Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992;25:231-241.
23. Bourhis J, Fortin A, Dupuis O, et al. Very accelerated radiation therapy: preliminary results in locally unresectable head and neck carcinomas. Int J Radiat Oncol Biol Phys 1995;32:747-752.
24. Bourhis J, Lapeyre M, Tortochaux J, et al. Very accelerated versus conventional radiotherapy in HNSCC: results of the GORTEC 94-02 randomized trial. Int J Radiat Oncol Biol Phys 2000;48 (Suppl):S111.
25. Van den Bogaert W, van der Schueren E, Horiot JC, et al. The feasibility of high-dose multiple daily fractionation and its combination with anoxic cell sensitizers in the treatment of head and neck cancer. A pilot study of the Radiotherapy Group of the EORTC (European Organisation for Research and Treatment of Cancer). Int J Radiat Oncol Biol Phys 1982;8:1649-1655.
26. Van den Bogaert W, van der Schueren E, Van Tongelen C, et al. Late results of multiple fractions per day (MFD) with misonidazole in advanced cancer of the head and neck. A pilot study of the EORTC radiotherapy group. Radiother Oncol 1985;3:139-144.
27. Van den Bogaert W, van der Schueren E, Horiot JC, et al. Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1986;12:587-591.
28. Van den Bogaert W, van der Schueren E, Horiot JC, et al. The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side-effects. Radiother Oncol 1995;35:91-99.
29. Van den Bogaert W, van der Schueren E, Horiot JC, et al. The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors. Radiother Oncol 1995;35:100-106.
30. Horiot JC, Bontemps P, Van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves locoregional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997;44:111-121.
31. Poulsen MG, Denham JW, Peters LJ, et al. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group study. Radiother Oncol 2001;60:113-122.
32. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 & 7 randomised controlled trial. Lancet 2003;362:933-940.
33. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation therapy for head and neck squamous cell carcinomas: first report of RTOG 90-03. Int J Radiat Oncol Biol Phys 2000;48:7-16.
34. Van der Schueren E, Van den Bogaert W, Vanuytsel L, Van Limbergen E. Radiotherapy by multiple fractions per day (MFD) in head and neck cancer: acute reactions of skin and mucosa. Int J Radiat Oncol Biol Phys 1990;19:301-311.
35. Kaanders JH, van der Kogel AJ, Ang KK. Altered fractionation: limited by mucosal reactions? Radiother Oncol 1998;50:247-260.
36. Khalil AA, Bentzen SM, Bernier J, et al. Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head and neck carcinomas. Int J Radiat Oncol Biol Phys 2003;55:568-575.
37. Bourhis J, Audry H, Overgaard J, et al. Meta-analysis of conventional versus altered fractionated radiotherapy in head and neck squamous cell carcinoma (HNSCC): final analysis. Int J Radiat Oncol Biol Phys 2004;60 (Suppl):S190-S191.
38. Pignon JP, Bourhis J, Domenge C, Designe L, on behalf of the MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000;355:949-955.
39. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L, for the Cancer Care Ontario Practice Guideline Initiative Head and Neck Cancer disease Site Group. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001;23:579-589.
40. Lau H, Brar S, Hao D, MacKinnon J, Yee D, Gluck S. Concomitant low-dose cisplatinum and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: analysis of survival and toxicity. Head Neck 2006;28:189-196.
41. Cooper JS, Ang KK. Concomitant chemotherapy and radiation therapy certainly improves local control. Int J Radiat Oncol Biol Phys 2005;61:7-9.
42. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-1804.
43. Bartelink H, Van den Bogaert W, Horiot JC, Jager J, van Glabbeke M. Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomized phase II EORTC trial. Eur J Cancer 2002;38:667-673.
44. Ang KK, Harris J, Garden AS, et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation Therapy Oncology Group phase II trial 99-14. J Clin Oncol 2005;23:3008-3015.
45. Bensadoun RJ, Benezery K, Dassonville O, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 2006;64:983-994.
46. Pignon T, Horiot JC, Van den Bogaert W, Van Glabbeke M, Scalliet P. No age limit for radical radiotherapy in head and neck tumours. Eur J Cancer 1996;32:2075-2081.
47. Maes A, Weltens C, Flamen P, et al. Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol 2002;63:203-211.
48. Bussels B, Maes A, Flamen P, et al. Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiother Oncol 2004;73:297-306.
49. Bussels B, Maes A, Hermans R, Nuyts S, Weltens C, Van den Bogaert W. Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer. Radiother Oncol 2004;72:119-127.
50. Marcial VA, Pajak TF, Chang C, Tupchong L, Stetz J. Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: preliminary report by the Radiation Therapy Oncology Group (RTOG). Int J Radiat Oncol Biol Phys 1978;13:41-47.
51. Lee DJ, Pajak T, Marcial VA, et al. Results from an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 1995;32:567-576.
52. Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997;44:123-136.
53. Fu KK, Clery M, Ang KK, Byhardt RW, Maor MH, Beitler JJ. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09. Int J Radiat Oncol Biol Phys 1995;32:589-597.
54. Beckmann GK, Hoppe F, Pfreudner L, Flentje MP. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck 2005;27:36-43.